Apogem Capital’s Johnson & Johnson JNJ Stock Holding History

Apogem Capital’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,261	Closed	-$369K	–	57
2022 Q3	$369K	Buy	+2,261	New	+$383K	0.37%	89

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Apogem Capital's JNJ Position: Q4 2022 in Review

Apogem Capital sold out of Johnson & Johnson (JNJ) in Q4 2022, closing a stake of 2,261 shares — an estimated $369K sold.

Apogem Capital first reported a position in JNJ in Q3 2022 and held it in 1 quarter. The position peaked at $369K in Q3 2022. 3,788 funds tracked by Wall St. Rank hold JNJ as of Q4 2022.

Apogem Capital reported no remaining Johnson & Johnson position as of Q4 2022 after selling out during the quarter.
Apogem Capital sold 2,261 Johnson & Johnson shares in Q4 2022, an estimated $369K.
Apogem Capital first reported a position in Johnson & Johnson in Q3 2022 and held it in 1 quarter.
Apogem Capital's Johnson & Johnson position peaked at $369K in Q3 2022.
3,788 funds tracked by Wall St. Rank held Johnson & Johnson as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.